CJ Wang – CEO, Frontier Biotech, China
Dr CJ Wang, CEO of Frontier Biotech, shares his exciting ten-year journey with Frontier and their distinctive focus on HIV drug development, with their flagship compound, Aikening®, launched in China…
Address: Rongjing Dong Street, Beijing Economic and Technological Development Zone Zip: 100176
Tel: -111549.584415584
Web: http://www.biotechplc.com/
BioteQ Bio-Pharmaceutical Co., Ltd. was established in August 2000, China and Cuba in the field of biotechnology, the highest level, the largest investment cooperation projects, to research and development and production of the treatment of malignant tumors, the source resistance, monoclonal antibodies and vaccines undertake the major projects of the National High-Tech Research and Development Plan, the national high-tech industrialization demonstration project for the main direction.
100 Thai Biological Pharmaceutical has China’s first world-class antibodies humanized technology platform, represents a core technology of the international bio-pharmaceutical development and direction of the mainstream. The company designed and built the production line of China’s first fully automated large-scale mammalian cell culture, which is currently the largest, most comprehensive facilities, the most technologically advanced large-scale cell culture technology platform.
The Biological Pharmaceutical Baitai successfully developed China’s first personal humanized monoclonal antibody drug – Taixinsheng nimotuzumab the drug in April 2005 Biology I class drug certificate issued by the State Food and Drug Administration , fill our humanized monoclonal antibody drugs blank. The Taixinsheng ® can specifically target the tumor cells to targeted therapies in killing tumor cells without damaging normal tissue, and represent the latest developments in the direction of the field of cancer treatment. Clinical studies have shown that Taixinsheng ® single-agent or combined radiotherapy and chemotherapy for head and neck cancer, colorectal cancer, glioma, non-small cell lung cancer efficacy, significant side effects is low, with high clinical value.
Same time the Biological Pharmaceutical Baitai actively carry out international technical transformation, is committed to nurturing the capability of independent innovation, new drugs are being developed, including the EGF vaccine for the treatment of cancer, psoriasis and rheumatoid arthritis, a humanized anti-CD6 single anti for reversal of organ transplant rejection anti-CD3 mAb.
The Biological Pharmaceutical development Baitai target large modern biopharmaceutical company, to improve antibody drug research and development capabilities and production levels, to improve the health of the people for the purpose, internationalization, industrialization, standardization, the scale of the operation mode, is committed to the latest achievements of the development of biotechnology into the cause of the health of the 21st century, and continuous dedication to the community is the most advanced, most excellent antibody drugs, witnessed the rise of China’s life sciences and biomedicine with you!
Research and Development
Dr CJ Wang, CEO of Frontier Biotech, shares his exciting ten-year journey with Frontier and their distinctive focus on HIV drug development, with their flagship compound, Aikening®, launched in China…
Dr Laura Benjamin, CEO of Oncologie, shares the rationale behind their exceptional decision to simultaneously establish offices in both the US and China; their unique biomarker approach focusing on the…
Shirley Xu, president of Baxter Greater China, reflects on her extraordinary 26-year (and counting) career with Baxter China, including her perspectives on the success factors behind Baxter’s growth in the…
John Moller, CEO; and Yooni Kim, executive director of Asia operations, for Novotech, share the competitive positioning of Novotech as a full-service CRO for biotech companies interested in the Asia-Pacific…
China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their drugs even further in the latest bidding war.…
Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary…
Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration with Jiangsu Hengrui (China’s largest pharma company by market capitalization),…
Geoff Kau, Co-GM and CSO of Ping An Smart City, introduces the breathtaking breadth of the Ping An healthcare ecosystem, and the interesting projects his subsidiary, Ping An Smart City,…
Charles Bark, CEO and founder of HiNounou, shares the touching personal story of what inspired him to establish HiNounou as a complete remote healthcare solution package for elderly people; how…
China-born entrepreneurs are returning to their homeland to find an industry filled with incentives in place for innovation, independent of generics. Here, we highlight five unique biotechs looking to serve…
An exclusive interview with Jason Smith, SVP (Asia Pacific, Middle East and Africa); Gerry Muhle, VP (International Medical Aesthetics); and White Wang, China President, of Allergan, at the inauguration ceremony…
Wang Wei of Winhealth Pharma, one of China’s leading contract development and commercialisation organisations, outlines the rationale behind the company’s formation, how its business model is changing to keep up…
See our Cookie Privacy Policy Here